Skip to main content
Erschienen in: Journal of Radiation Oncology 1-2/2020

24.05.2020 | Original Research

Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery

verfasst von: Lucas Resende Salgado, Andrew W. Smith, Anthony Nehlsen, Alexandra Cohen, Tzu-Chi Tseng, Jung-Yi Lin, Erin Moshier, Michael Buckstein, Richard Bakst, Isabelle M. Germano, Sheryl Green

Erschienen in: Journal of Radiation Oncology | Ausgabe 1-2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Biological subtypes have been strongly correlated with loco-regional recurrence after definitive treatment for localized breast cancer. Brain metastases (BM) occur in 15% of patient diagnosed with breast cancer (BC). Therefore, we sought to determine whether biologic subtype is predictive of local control (LC) in BC patients with BM treated with stereotactic radiosurgery (SRS).

Methods

This is a single-center retrospective study conducted with Institutional Review Board approval for the period January 1, 2004–December 31, 2018. Eligibility criteria included (1) histopathologic proven BC with documented biologic subtype, (2) presence of BM treated with SRS (single fraction), (3) follow-up MRIs, and (4) clinical follow-up. Patients were subdivided into three biologic subtypes: ER+/HER2- (“luminal”), HER2+, and ER-/PR-/HER2 (TN). All patients were treated with LINAC-based SRS with dose according to published guidelines. Cox proportional hazard model and Kaplan-Meier were used for statistical analysis of LC and overall survival (OS).

Results

With a median follow-up of 11.1 months, 17 BC BM in 50 consecutive patients were included in this study. The median disease-specific GPA was 2.0, and all patients received systemic chemotherapy and/or hormonal therapy. The 12-month LC rates for the entire cohort were 85%, 87%, and 49% for luminal, HER2+, and TN, respectively, with a significantly shorter time to local failure for the TN subtype (p = 0.014). The 12-month OS rates were 83%, 88%, and 80% for luminal, HER2+, and TN, respectively, with a trend toward shorter OS in the TN group.

Conclusion

This study shows that in BC patients with BM treated with SRS, biologic subtype affects LC. Consideration of radiation treatment intensification or altered fractionation to improve LC may be indicated for the TN subtype. Further multicenter studies are necessary to corroborate our results.
Literatur
1.
Zurück zum Zitat Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7(3):337–344CrossRefPubMed Johnson JD, Young B (1996) Demographics of brain metastasis. Neurosurg Clin N Am 7(3):337–344CrossRefPubMed
2.
Zurück zum Zitat Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology 13(7):941–954 57–61; discussion 61–2, 9PubMed Wen PY, Loeffler JS (1999) Management of brain metastases. Oncology 13(7):941–954 57–61; discussion 61–2, 9PubMed
3.
Zurück zum Zitat Posner JB (1992) Management of brain metastases. Rev Neurol 148(6–7):477–487PubMed Posner JB (1992) Management of brain metastases. Rev Neurol 148(6–7):477–487PubMed
4.
Zurück zum Zitat Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49(4):651–654CrossRefPubMed Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49(4):651–654CrossRefPubMed
5.
Zurück zum Zitat Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113CrossRefPubMed Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5(2):108–113CrossRefPubMed
6.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872CrossRefPubMed Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872CrossRefPubMed
7.
Zurück zum Zitat Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMed Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMed
8.
Zurück zum Zitat Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705CrossRefPubMed Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705CrossRefPubMed
9.
Zurück zum Zitat Horton JK, Jagsi R, Woodward WA, Ho A (2018) Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 100(1):23–37CrossRefPubMed Horton JK, Jagsi R, Woodward WA, Ho A (2018) Breast cancer biology: clinical implications for breast radiation therapy. Int J Radiat Oncol Biol Phys 100(1):23–37CrossRefPubMed
10.
Zurück zum Zitat Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Jnci-J Natl Cancer I 106(5) Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Jnci-J Natl Cancer I 106(5)
11.
Zurück zum Zitat Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980–1989PubMed Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980–1989PubMed
12.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed
13.
Zurück zum Zitat Breast Cancer Staging System (2018) AJCC cancer staging manual, Eight Edition Breast Cancer Staging System (2018) AJCC cancer staging manual, Eight Edition
14.
Zurück zum Zitat Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160CrossRefPubMed Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160CrossRefPubMed
15.
Zurück zum Zitat Millar EK, Graham PH, O'Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701–4708CrossRefPubMed Millar EK, Graham PH, O'Toole SA et al (2009) Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 27(28):4701–4708CrossRefPubMed
16.
Zurück zum Zitat Wang YH, Yin QG, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498CrossRefPubMed Wang YH, Yin QG, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y (2011) A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2):489–498CrossRefPubMed
17.
Zurück zum Zitat Merino T, Ip T, Dominguez F et al (2018) Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study. Oncotarget 9(54):30355–30362CrossRefPubMedPubMedCentral Merino T, Ip T, Dominguez F et al (2018) Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study. Oncotarget 9(54):30355–30362CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Langlands FE, Horgan K, Dodwell DD, Smith L (2013) Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Brit J Radiol 86(1023) Langlands FE, Horgan K, Dodwell DD, Smith L (2013) Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Brit J Radiol 86(1023)
19.
Zurück zum Zitat Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123(12):2283–2293CrossRefPubMed Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH (2017) Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer 123(12):2283–2293CrossRefPubMed
20.
Zurück zum Zitat Buatti JM, Friedman WA, Meeks SL, Bova FJ (2000) RTOG 90-05: the real conclusion. Int J Radiat Oncol Biol Phys 47(2):269–271CrossRefPubMed Buatti JM, Friedman WA, Meeks SL, Bova FJ (2000) RTOG 90-05: the real conclusion. Int J Radiat Oncol Biol Phys 47(2):269–271CrossRefPubMed
21.
Zurück zum Zitat Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentral Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Lee EW, Wei LJ, Amato DA, Leurgans S (1992) Cox-type regression-analysis for large numbers of small-groups of correlated failure time observations. Nato Adv Sci I E-App 211:237–247 Lee EW, Wei LJ, Amato DA, Leurgans S (1992) Cox-type regression-analysis for large numbers of small-groups of correlated failure time observations. Nato Adv Sci I E-App 211:237–247
23.
Zurück zum Zitat Shtatland ES, Barton MB (1998) An information-gain measure of fit in PROC LOGISTIC. In: Proceedings of the Twenty-Third Annual Sas Users Group International Conference. pp 1195–9 Shtatland ES, Barton MB (1998) An information-gain measure of fit in PROC LOGISTIC. In: Proceedings of the Twenty-Third Annual Sas Users Group International Conference. pp 1195–9
24.
Zurück zum Zitat DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918CrossRefPubMed DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918CrossRefPubMed
25.
Zurück zum Zitat Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Anna Oncol 20(1):56–62CrossRef Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH (2009) Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Anna Oncol 20(1):56–62CrossRef
26.
Zurück zum Zitat Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894–900CrossRefPubMedPubMedCentral Park YH, Park MJ, Ji SH, Yi SY, Lim DH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Ahn JS, Kang WK, Park K, Im YH (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100(6):894–900CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242–1248CrossRefPubMed Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242–1248CrossRefPubMed
28.
Zurück zum Zitat Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast Cancer: a population-based study. JAMA Oncol 3(8):1069–1077CrossRefPubMedPubMedCentral Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast Cancer: a population-based study. JAMA Oncol 3(8):1069–1077CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Bastos DCA, Maldaun MVC, Sawaya R et al (2018) Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neuro-Oncol Pract 5(3):161–169CrossRef Bastos DCA, Maldaun MVC, Sawaya R et al (2018) Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neuro-Oncol Pract 5(3):161–169CrossRef
30.
Zurück zum Zitat Suzuki S, Inoue T, Ishido K (2016) Factors influencing local tumor control after gamma knife radiosurgery for intracranial metastases from breast cancer. J Clin Neurosci 33:154–158CrossRefPubMed Suzuki S, Inoue T, Ishido K (2016) Factors influencing local tumor control after gamma knife radiosurgery for intracranial metastases from breast cancer. J Clin Neurosci 33:154–158CrossRefPubMed
31.
Zurück zum Zitat Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM (2012) Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol 83(4):E479–EE86CrossRef Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM (2012) Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol 83(4):E479–EE86CrossRef
32.
Zurück zum Zitat Wen Y, Dai G, Wang L, Fu K, Zuo S (2019) Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells. Biosci Rep 39(3) Wen Y, Dai G, Wang L, Fu K, Zuo S (2019) Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells. Biosci Rep 39(3)
33.
Zurück zum Zitat Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, Osti M, Enrici RM, Esposito V (2016) Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large ( > 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol 95(4):1142–1148CrossRef Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F, Osti M, Enrici RM, Esposito V (2016) Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large ( > 2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol 95(4):1142–1148CrossRef
34.
Zurück zum Zitat Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent M, Vogelbaum MA, Wen PY, Response Assessment in Neuro-Oncology (RANO) group (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):E270–E2E8CrossRefPubMed Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent M, Vogelbaum MA, Wen PY, Response Assessment in Neuro-Oncology (RANO) group (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):E270–E2E8CrossRefPubMed
Metadaten
Titel
Biologic subtypes as a predictor of local control in patients with brain metastases from breast cancer after stereotactic radiosurgery
verfasst von
Lucas Resende Salgado
Andrew W. Smith
Anthony Nehlsen
Alexandra Cohen
Tzu-Chi Tseng
Jung-Yi Lin
Erin Moshier
Michael Buckstein
Richard Bakst
Isabelle M. Germano
Sheryl Green
Publikationsdatum
24.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 1-2/2020
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-020-00424-0

Weitere Artikel der Ausgabe 1-2/2020

Journal of Radiation Oncology 1-2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.